1. Home
  2. BLFS vs AVLN Comparison

BLFS vs AVLN Comparison

Compare BLFS & AVLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BioLife Solutions Inc.

BLFS

BioLife Solutions Inc.

HOLD

Current Price

$29.10

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Logo Avalyn Pharma Inc. Common Stock

AVLN

Avalyn Pharma Inc. Common Stock

N/A

Current Price

$28.69

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BLFS
AVLN
Founded
1987
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.3B
IPO Year
2013
2026

Fundamental Metrics

Financial Performance
Metric
BLFS
AVLN
Price
$29.10
$28.69
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$32.00
N/A
AVG Volume (30 Days)
1.0M
462.0K
Earning Date
05-07-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
77.27
N/A
EPS
0.02
N/A
Revenue
$96,214,000.00
N/A
Revenue This Year
$19.73
N/A
Revenue Next Year
$17.82
N/A
P/E Ratio
$1,511.25
N/A
Revenue Growth
16.97
N/A
52 Week Low
$17.86
$25.07
52 Week High
$30.27
$33.32

Technical Indicators

Market Signals
Indicator
BLFS
AVLN
Relative Strength Index (RSI) 59.71 40.12
Support Level $23.86 $27.22
Resistance Level $29.18 $29.31
Average True Range (ATR) 1.29 2.30
MACD 0.06 -0.19
Stochastic Oscillator 57.08 40.62

Price Performance

Historical Comparison
BLFS
AVLN

About BLFS BioLife Solutions Inc.

BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.

About AVLN Avalyn Pharma Inc. Common Stock

Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.

Share on Social Networks: